Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to $11.0 million.

  • Legend Biotech's Other Non-Current Assets rose 46884.06% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 46884.06%. This contributed to the annual value of $13.0 million for FY2024, which is 76751.51% up from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Other Non-Current Assets is $11.0 million, which was up 46884.06% from $5.7 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Other Non-Current Assets registered a high of $24.6 million during Q1 2022, and its lowest value of $3983.0 during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.9 million (2024), whereas its average is $5.1 million.
  • In the last 5 years, Legend Biotech's Other Non-Current Assets surged by 61810236.0% in 2022 and then tumbled by 9568.7% in 2023.
  • Legend Biotech's Other Non-Current Assets (Quarter) stood at $5.1 million in 2021, then crashed by 71.11% to $1.5 million in 2022, then rose by 0.4% to $1.5 million in 2023, then surged by 767.52% to $13.0 million in 2024, then decreased by 15.15% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $5.7 million for Q2 2025, and $5.6 million during Q1 2025.